Xencor, Inc. (NASDAQ:XNCR) Shares Bought by Primecap Management Co. CA

Primecap Management Co. CA lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,116,202 shares of the biopharmaceutical company’s stock after buying an additional 25,495 shares during the quarter. Primecap Management Co. CA owned approximately 0.15% of Xencor worth $172,570,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Renaissance Technologies LLC grew its holdings in Xencor by 49.8% during the 2nd quarter. Renaissance Technologies LLC now owns 65,323 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 21,723 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Xencor by 6.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after purchasing an additional 87,979 shares during the last quarter. WINTON GROUP Ltd grew its stake in Xencor by 4.2% in the second quarter. WINTON GROUP Ltd now owns 46,481 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 1,883 shares in the last quarter. American Century Companies Inc. increased its holdings in Xencor by 14.5% in the second quarter. American Century Companies Inc. now owns 95,375 shares of the biopharmaceutical company’s stock valued at $1,805,000 after buying an additional 12,083 shares during the last quarter. Finally, Quest Partners LLC raised its stake in Xencor by 121.2% during the second quarter. Quest Partners LLC now owns 18,639 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 10,214 shares in the last quarter.

Insider Activity at Xencor

In other Xencor news, VP John R. Desjarlais sold 36,329 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the transaction, the vice president now owns 192,319 shares in the company, valued at approximately $3,523,284.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.23% of the stock is owned by insiders.

Xencor Trading Down 1.5 %

Shares of NASDAQ:XNCR opened at $21.15 on Tuesday. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $18.43 and its 200 day moving average price is $20.48. The company has a market cap of $1.31 billion, a PE ratio of -9.66 and a beta of 0.66. Xencor, Inc. has a fifty-two week low of $15.31 and a fifty-two week high of $26.84.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The firm had revenue of $16.96 million during the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. Xencor’s revenue for the quarter was down 62.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.37) EPS. Sell-side analysts anticipate that Xencor, Inc. will post -4.17 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on XNCR. Raymond James decreased their target price on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of Xencor in a research note on Tuesday, August 6th. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Xencor in a report on Monday, September 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Xencor in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average price target of $34.44.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.